CS
FDMT icon

Candriam SCA’s 4D Molecular Therapeutics FDMT Stock Holding History

Candriam SCA’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-269,000
Closed -$8.57M – 700
2024
Q1 		$8.57M Buy
269,000
+71,000
+36% +$1.81M 0.05% 273
2023
Q4 		$4.01M Hold
198,000
– – 0.03% 366
2023
Q3 		$2.52M Buy
198,000
+25,000
+14% +$418K 0.02% 416
2023
Q2 		$3.13M Sell
173,000
-62,000
-26% -$1.14M 0.02% 419
2023
Q1 		$3.72M Buy
+235,000
New +$4.57M 0.03% 428

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA's FDMT Position: Q2 2024 in Review

Candriam SCA sold out of 4D Molecular Therapeutics (FDMT) in Q2 2024, closing a stake of 269,000 shares — an estimated $8.57M sold.

Candriam SCA first reported a position in FDMT in Q1 2023 and held it in 5 quarters. The position peaked at $8.57M in Q1 2024. 143 funds tracked by Wall St. Rank hold FDMT as of Q2 2024.

  • Candriam SCA reported no remaining 4D Molecular Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Candriam SCA sold 269,000 4D Molecular Therapeutics shares in Q2 2024, an estimated $8.57M.
  • Candriam SCA first reported a position in 4D Molecular Therapeutics in Q1 2023 and held it in 5 quarters.
  • Candriam SCA's 4D Molecular Therapeutics position peaked at $8.57M in Q1 2024.
  • 143 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.